Skip to main content
. 2023 Dec 7;7(12):e0344. doi: 10.1097/HC9.0000000000000344

TABLE 3.

Association of diabetes status with HCC

Predictor SHR 95% CI
Diabetes 1.18 1.13–1.24
Etiology of cirrhosis
 MASLD Ref
 Alcohol 1.22 1.12–1.34
 Alcohol/HCV 2.94 2.52–3.44
 HCV 2.94 2.54–3.42
 HBV 1.47 1.14–1.88
 Other 1.06 0.88–1.27
HCV treatment status
 Non-HCV cirrhosis Ref
 HCV treated by DAA, cleared 0.13 0.11–0.15
 HCV cleared (non-DAA) 0.05 0.03–0.07
 HCV treated by DAA, not cleared No est No est
 HCV not treated, not cleared 2.34 2.04–2.67
Baseline CTP class
 A Ref
 B 0.59 0.56–0.63
 C 0.46 0.40–0.53
Statin use 0.69 0.65–0.73
AUDIT-C
 Low risk Ref
 Moderate risk 0.95 0.87–1.04
 High risk 0.90 0.80–1.01
 Severe risk 0.76 0.70–0.83
Age (per y) 1.01 1.01–1.01
Male sex 1.83 1.51–2.21
Race/ethnicity
 Non-Hispanic White Ref
 Black 0.94 0.89–1.00
 Asian 1.23 1.02–1.48
 Hispanic 1.04 0.96–1.13
 Native American 1.12 0.92–1.37
 Other 0.84 0.77–0.91
BMI (per point increase) 1.01 1.01–1.01
Tobacco use
 Never Ref
 Former 1.05 0.99–1.11
 Current 1.00 0.94–1.06
Annual primary care visits 0.99 0.98–1.00
Annual GI/hepatology visits 1.02 1.01–1.03

Note: Missing data for covariables was present as follows: HCV treatment status, n = 38, AUDIT-C, n = 291, smoking status, n = 1136, BMI n = 292.

Abbreviations: AUDIT-C, Alcohol Use Disorders Identification Test-Consumption; BMI, body mass index; CTP Child-Turcotte-Pugh; DAA, direct-acting antivirals; MASLD, metabolic dysfunction–associated steatotic liver disease; SHR, subdistribution HR.